Goldfinch Bio, a Cambridge, Mass., biotech startup seeking to develop precision medicines for people with kidney disease, will receive at least $109 million in a business deal with the California biopharma giant Gilead Sciences (GILD).

It’s the first major business deal cut by Goldfinch since the privately held company was created in 2016 by the Boston venture capital firm Third Rock Ventures.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy